Full text is available at the source.
Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond
Glucagon-like peptide-1 receptor agonists and their potential to improve heart and kidney health: findings from FLOW and other studies
AI simplified
Abstract
GLP1 receptor agonists have been shown to reduce kidney failure and cardiovascular mortality by 24% in patients with type 2 diabetes.
- Clinical trials indicate that GLP1 receptor agonists are associated with fewer major adverse cardiovascular events.
- The FLOW trial specifically demonstrated that semaglutide leads to significant reductions in kidney-related outcomes.
- Favorable effects on kidney health have also been observed in nondiabetic individuals with overweight or obesity.
- Dedicated trials suggest that these medications can lower the risk of hospitalization for heart failure and improve related symptoms.
- Subgroup analyses imply that cardiorenal benefits may occur regardless of other medications being used.
AI simplified